1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 13

    Importance of e-liquid preparation and stability characterization for a combinatorial safety assessment approach of flavors in e-liquids

    GLABASNIA A.(1); DIANA P.(1); SMITH C.(2); MILLER J.H.(2); BIASIOLI M.(1); FRAUENDORFER F.(1); SCIUSCIO D.(1); MARTIN E.(1); POSPISIL P.(1); GUY P.(1); VANSCHEEUWIJCK P.(1); HOENG J.(1); KUMAR A.(2); LEE K.M.(2)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Altria Client Services LLC, Richmond, VA, U.S.A.
    Numerous flavorings are generally recognized as safe for use in food, but there is limited information available to evaluate their potential toxicity by inhalation. Consequently, gaining information on individual flavor safety levels is of significant ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 47

    A high-throughput and sensitive bioanalytical method for quantification of nicotine and cotinine in rat/mouse plasma using reversed-phase liquid chromatography–tandem mass spectrometry and its application in inhalation study sample analysis

    SAXENA A.(1); ZHANG Chunyan(1); CIPUTRA T.(1); CHNG Yun Xuan(1); PHILLIPS B.(1); VANSCHEEUWIJCK P.(2)
    (1) PMI R&D, Philip Morris International Research Laboratories Pte. Ltd., Singapore; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland
    Nicotine and cotinine are used as primary biomarkers to estimate the exposure of reduced-risk products, such as e-liquids/heated tobacco products, in comparison with cigarettes. The objective of this study was to develop and validate a method per current ...
  3. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 103

    Preclinical testing of flavors in e-vapor products - Part 1: Selection of representative flavor mixtures for toxicological evaluations using a structural grouping approach

    EHMAN K.D.(1); LANGSTON T.B.(1); KUMAR A.(1); LEE K.M.(1); SCIUSCIO D.(2); VANSCHEEUWIJCK P.(2); HOENG J.(2)
    (1) Altria Client Services, Richmond, VA, USA; (2) PMI R&D, Neuchâtel, Switzerland
    A variety of flavor ingredients are used in potentially reduced-risk tobacco or nicotine products, including e-vapor products. For this work, the ingredients were initially evaluated for quality and purity, which included assessment of food grade and GRAS ...
  4. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 04

    Assessing the cytotoxicity of e-liquids without the use of the neutral red uptake assay

    McHUGH D.; CUDAZZO G.; VANSCHEEUWIJCK P.
    Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland
    As part of the pre-clinical assessment performed for consumer products in the tobacco industry, an in vitro assessment of a tobacco product’s cytotoxicity was performed using the neutral red uptake (NRU) assay. Since 2004, the CORESTA In Vitro Task Force ...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 48

    Six-month systems toxicology inhalation/cessation study in ApoE-/- mice to investigate cardiovascular and respiratory exposure effects of two reduced risk tobacco products compared with conventional cigarettes

    PHILLIPS B.(2); SZOSTAK J.(1); HO J.(2); GUEDJ E.(1); WONG Ee Tsin(2); TALIKKA M.(1); LEBRUN S.(1); TITZ B.(1); MARTIN F.(1); VUILLAUME G.(1); LEROY P.(1); IVANOV N.(1); VANSCHEEUWIJCK P.(1); PEITSCH M.C.(1); HOENG J.(1)
    (1) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (2) Philip Morris International Research Laboratories Pte. Ltd., (part of Philip Morris International group of companies), PMI R&D, Singapore
    Cigarette smoking causes adverse health effects that may occur shortly after smoking initiation and lead to the development of cardiovascular disease, respiratory disease (chronic obstructive pulmonary disease), and various cancers. To reduce the risk of ...
  6. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, STPOST 61

    A 6-month inhalation study in Apoe-/- mice to investigate cardiovascular and respiratory exposure effects of e-vapor aerosols compared with cigarette smoke

    WONG Ee Tsin(1); SZOSTAK J.(2); KRISHNAN S.(1); TAN Wei Teck(1); SEOW E.(1); TENG C.(1); LEE K.M.(3); ZHANG Jingjie(3); McKINNEY W.J.(3); PEITSCH M.C.(2); VANSCHEEUWIJCK P.(2); HOENG J.(2)
    (1) Philip Morris International Research Laboratories Pte. Ltd., (part of Philip Morris International group of companies), PMI R&D, Singapore; (2) Philip Morris Products S.A. (part of Philip Morris International group of companies), PMI R&D, Neuchâtel, Switzerland; (3) Altria Client Services LLC, Richmond, VA, U.S.A.
    Chronic exposure to cigarette smoke is a risk factor for the development and progression of cardiovascular disease and chronic obstructive pulmonary disease. Considerable attention has been given towards the potential reduced harm of e cigarettes (e cigs) ...